340B Drug Pricing Program Update: Temporary Hold on All Retrospective Recoveries and Prospective Edits

Changes that affect how we reimburse for payable drugs and biological agents purchased through the 340B Drug Pricing Program was communicated in a June 2018 letter to care providers as well as an article that appeared in the July 2018 edition of the Network Bulletin.

Based on feedback we’ve received from care providers, we have placed a temporary hold to further review our process for reimbursing drugs purchased through the 340B program. This temporary hold also allows time for care providers to review their process to ensure they are appropriately submitting claims for drugs purchased through the 340B program. This hold also allows care providers time to provide supporting documentation to demonstrate reimbursement should be made at the higher rate for drugs not purchased through the 340B program.

As a reminder, claims for separately payable Outpatient Prospective Payment System (OPPS) drugs or biologicals purchased through the 340B program must include the appropriate modifier. The Centers for Medicare & Medicaid Services (CMS) has established two HCPCS Level II modifiers to identify 340B acquired drugs – modifiers “JG” and “TB.”

For more information on submitting corrected claims or providing supporting documentation, please visit UHCprovider.com.

We’re Here to Help
If you have questions about the temporary hold placed on the 340B Drug Pricing Program, please contact your Network Representative.